Syros Pharmaceuticals, Inc. (SYRS)
OTCMKTS · Delayed Price · Currency is USD
0.0002
0.00 (0.00%)
May 27, 2026, 3:44 PM EST
Syros Pharmaceuticals Revenue
Syros Pharmaceuticals had revenue of $386.00K in the twelve months ending September 30, 2024, down -95.61% year-over-year. In the year 2023, Syros Pharmaceuticals had annual revenue of $9.94M, down -33.23%.
Revenue (ttm)
386.00K
Revenue Growth
-95.61%
P/S Ratio
0.01
Revenue / Employee
5.68K
Employees
68
Market Cap
5.37K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9.94M | -4.94M | -33.23% |
| Dec 31, 2022 | 14.88M | -8.61M | -36.65% |
| Dec 31, 2021 | 23.49M | 8.40M | 55.62% |
| Dec 31, 2020 | 15.09M | 13.11M | 661.50% |
| Dec 31, 2019 | 1.98M | -68.00K | -3.32% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ObsEva | 19.64M |
| Statera Biopharma | 3.69M |
| GeneLink | 1.58M |
| Trevena | 546.00K |
| Bioasis Technologies | 199.01K |
| Therapeutic Solutions International | 85.32K |
Syros Pharmaceuticals News
- 1 year ago - Syros Pharmaceuticals sells Tamibarotene assets to Rege Nephro - TheFly
- 1 year ago - Syros Pharmaceuticals trading resumes - TheFly
- 1 year ago - Syros Pharmaceuticals voluntarily delists from Nasdaq, deregisters common stock - TheFly
- 1 year ago - Syros Pharmaceuticals trading halted, news pending - TheFly
- 1 year ago - Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration - Business Wire
- 1 year ago - Syros Pharmaceuticals downgraded to Hold from Buy at TD Cowen - TheFly
- 1 year ago - Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 1 year ago - Syros downgraded to Market Perform from Outperform at JMP Securities - TheFly